Short answer
Tevogen Bio Holdings Inc. (TVGN) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$7M
- −22.3% YoY · −21.6% QoQ
- EPS (diluted)
- −$1.77
- −5800.0% YoY · −14.2% QoQ
Source: XBRL data from the Tevogen Bio Holdings Inc. (TVGN) Q3 2026 10-Q on SEC EDGAR. USD.
Tevogen Bio Holdings Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no products commercialized
- Operating margin not applicable, operating loss $6.9M vs $5.7M YoY
- Worst expense trend: G&A $3.9M vs $2.6M, driven by stock-based compensation
- Cash $0.1M vs $0.6M at December 31, 2025, operating cash use $7.7M
- Outlook: $28.6M borrowing availability and $7.0M committed grant, clinical trial deferred until manufacturing facility secured
Risk Factors
- No material risk-factor changes disclosed, with Item 1A containing no substantive risk-factor text
- Liquidity risk: $144,713 cash versus $6,371,539 current liabilities at September 30, 2026
- Financing risk: $1,651,000 notes payable remained in default following the Merger
- Dilution risk: up to approximately 4.99 million additional shares issuable under the amended Loan Agreement
- Clinical and regulatory risk: TVGN 489 and other candidates may fail development or required regulatory approval
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tevogen Bio Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.